Transcode Therapeutics Inc Total Assets
Transcode Therapeutics Inc total assets. Based on the latest financial reports, Transcode Therapeutics Inc (RNAZ) holds total assets worth $151.01 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Transcode Therapeutics Inc market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of Transcode Therapeutics Inc (2018–2025)
Total assets of Transcode Therapeutics Inc from 2018 to 2025. This chart illustrates how Transcode Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See RNAZ stock price for real-time trading data and today's change.
Transcode Therapeutics Inc - Asset Composition Analysis
Transcode Therapeutics Inc Total Assets Breakdown (December 2025)
Transcode Therapeutics Inc total assets breakdown as of December 2025. Transcode Therapeutics Inc's total assets of $151.01 Million consist of 13.5% current assets and 86.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 11.0% |
| Accounts Receivable | $3.25 Million | 2.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $114.30 Million | 70.4% |
| Goodwill | $25.74 Million | 15.9% |
Asset Composition Trend (2018–2025)
This chart illustrates how Transcode Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Transcode Therapeutics Inc working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Transcode Therapeutics Inc's current assets represent 13.5% of total assets in 2025, a decrease from 100.0% in 2018.
- Cash Position: Cash and equivalents constituted 11.0% of total assets in 2025, down from 99.2% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 85.0% of total assets, an increase from 0.0% in 2018.
- Asset Diversification: The largest asset category is intangible assets at 70.4% of total assets.
Transcode Therapeutics Inc Competitors by Total Assets
Key competitors of Transcode Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Transcode Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.97 | 5.27 | 11.43 |
| Quick Ratio | 1.97 | 5.27 | 11.43 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $5.24 Million | $6.68 Million | $23.00 Million |
Transcode Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Transcode Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.83 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 2126.3% |
| Total Assets | $162.40 Million |
| Market Capitalization | $1.66 Million USD |
Valuation Analysis
Below Book Valuation: The market values Transcode Therapeutics Inc's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Transcode Therapeutics Inc's assets grew by 2126.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Transcode Therapeutics Inc (2018–2025)
The table below shows the annual total assets of Transcode Therapeutics Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $162.40 Million | +2126.32% |
| 2024-12-31 | $7.29 Million | +41.10% |
| 2023-12-31 | $5.17 Million | -31.87% |
| 2022-12-31 | $7.59 Million | -66.92% |
| 2021-12-31 | $22.94 Million | +2073.50% |
| 2020-12-31 | $1.06 Million | +386.92% |
| 2019-12-31 | $216.74K | +0.98% |
| 2018-12-31 | $214.65K | -- |
About Transcode Therapeutics Inc
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastati… Read more